{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T02:39:55Z","timestamp":1768876795641,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s41669-025-00592-0","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T14:30:50Z","timestamp":1754404250000},"page":"827-836","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Economic Evaluation of Treatment With Trastuzumab Deruxtecan for HER2-Low Advanced or Metastatic Breast Cancer in Previously Treated Patients"],"prefix":"10.1007","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3063-494X","authenticated-orcid":false,"given":"Silvia","family":"Fenix-Caballero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7876-1657","authenticated-orcid":false,"given":"Pablo","family":"Caleffa-Menendez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0179-6295","authenticated-orcid":false,"given":"Carmen Maria","family":"Dominguez-Santana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0041-2024","authenticated-orcid":false,"given":"Emilio Jesus","family":"Alegre-Del-Rey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5448-1370","authenticated-orcid":false,"given":"Antonio","family":"Olry de Labry Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"592_CR1","unstructured":"GEICAM - Investigaci\u00f3n en C\u00e1ncer de Mama, https:\/\/www.geicam.org\/sala-de-prensa\/el-cancer-de-mama-en-espana; 2024. Accessed 20 Aug 2024."},{"issue":"1","key":"592_CR2","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3390\/cancers15010126","volume":"15","author":"H Zhang","year":"2022","unstructured":"Zhang H, Peng Y. Current Biological, Pathological and Clinical Landscape of HER2-Low Breast Cancer. Cancers (Basel). 2022;15(1):126. https:\/\/doi.org\/10.3390\/cancers15010126.","journal-title":"Cancers (Basel)."},{"issue":"1","key":"592_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, DESTINY-Breast04 Trial Investigators, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203690.","journal-title":"N Engl J Med"},{"key":"592_CR4","unstructured":"Agencia espa\u00f1ola de medicamentos y productos sanitarios. Informe de Posicionamiento Terap\u00e9utico de eribulina (Halaven\u00ae) en el c\u00e1ncer de mama, https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/eribulina-Halaven.pdf; 2015. Accessed 20 Aug 2024."},{"key":"592_CR5","unstructured":"Agencia espa\u00f1ola de medicamentos y productos sanitarios. Informe de Posicionamiento Terap\u00e9utico de sacituzumab govitec\u00e1n (Trodelvy\u00ae) en el tratamiento del c\u00e1ncer de mama triple negative, https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/2023\/IPT-096-2023-Trodelvy.pdf; 2023. Accessed 20 Aug 2024."},{"key":"592_CR6","unstructured":"Agencia espa\u00f1ola de medicamentos y productos sanitarios. Ficha t\u00e9cnica de Enhertu 100mg, https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1201508001\/FT_1201508001.html; 2024. Accessed 5 Aug 2024."},{"key":"592_CR7","unstructured":"Ministry of Health. Search Enghien for the situation of pharmaceutical Financing [Buscador de la Informaci\u00f3n sobre la situaci\u00f3n de financiaci\u00f3n de los medicamentos, BIFIMED], https:\/\/www.sanidad.gob.es\/profesionales\/medicamentos.do?metodo=verDetalle&cn=730318; 2024. Accessed 20 Aug 2024."},{"issue":"3","key":"592_CR8","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.vhri.2013.10.004","volume":"2","author":"F Augustovski","year":"2013","unstructured":"Augustovski F, Garc\u00eda Mart\u00ed S, Pichon-Riviere A. Est\u00e1ndares Consolidados de Reporte de Evaluaciones Econ\u00f3micas Sanitarias: Versi\u00f3n en Espa\u00f1ol de la Lista de Comprobaci\u00f3n CHEERS. Value Health Reg Issues. 2013;2(3):338\u201341. https:\/\/doi.org\/10.1016\/j.vhri.2013.10.004.","journal-title":"Value Health Reg Issues."},{"key":"592_CR9","unstructured":"NCCN Guidelines for Antiemesis V.1.2021, https:\/\/www.nccn.org\/guidelines\/guidelines-process\/transparency-process-and-recommendations\/GetFileFromFileManagerGuid?FileManagerGuidId=71182a7d-c2c4-4832-983c-59144bb13d66; 2020. Accessed 5 Aug 2024."},{"issue":"12","key":"592_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"1","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;1(12):9. https:\/\/doi.org\/10.1186\/1471-2288-12-9.","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"592_CR11","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1177\/0272989X12472398","volume":"33","author":"NR Latimer","year":"2013","unstructured":"Latimer NR. Survival analysis for economic evaluations alongside clinical trials\u2013extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med Decis Making. 2013;33(6):743\u201354. https:\/\/doi.org\/10.1177\/0272989X12472398.","journal-title":"Med Decis Making"},{"issue":"5","key":"592_CR12","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1080\/14737167.2016.1222907","volume":"16","author":"N Paracha","year":"2016","unstructured":"Paracha N, Thuresson PO, Moreno SG, MacGilchrist KS. Health state utility values in locally advanced and metastatic breast cancer by treatment line: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2016;16(5):549\u201359. https:\/\/doi.org\/10.1080\/14737167.2016.1222907.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"592_CR13","unstructured":"Rothschedl, E.\u00a0and\u00a0Wolf, S.\u00a0(2023):\u00a0Trastuzumab deruxtecan (Enhertu\u00ae) as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer. Update April 2023. Oncology Fact Sheet Nr. 120,https:\/\/eprints.aihta.at\/1427\/. Accessed 20 Aug 2024."},{"key":"592_CR14","unstructured":"Consejer\u00eda de Salud de la Junta de Andaluc\u00eda. Proceso Asistencial Integrado C\u00e1ncer de mama, 3\u00aa edici\u00f3n, https:\/\/juntadeandalucia.es\/organismos\/saludyconsumo\/areas\/calidad\/pai\/paginas\/pai-cancer-mama.html; 2011. Accessed 20 Aug 2024."},{"key":"592_CR15","unstructured":"Bot Plus 2, https:\/\/botplusweb.portalfarma.com; 2023. Accessed 12 Sep 2023."},{"key":"592_CR16","unstructured":"Ministerio de Sanidad - Profesionales de la Salud \u2013 Nomenclator, https:\/\/www.sanidad.gob.es\/profesionales\/nomenclator.do; 2024 [accessed 5 August 2024]."},{"key":"592_CR17","unstructured":"Junta de Andaluc\u00eda (2005). ORDEN de 14 de octubre de 2005, por la que se fijan los precios p\u00fablicos de los servicios sanitarios prestados por Centros dependientes del Sistema Sanitario P\u00fablico de Andaluc\u00eda. Bolet\u00edn Oficial de la Junta de Andaluc\u00eda (210), pp. 46-83.\u00a0https:\/\/juntadeandalucia.es\/boja\/2005\/210\/28; 2005. Accessed 20 Aug 2024."},{"key":"592_CR18","unstructured":"Junta de Andaluc\u00eda (2016). Orden de 8 de noviembre de 2016, por la que se modifica la Orden de 14 de octubre de 2005, por la que se fijan los precios p\u00fablicos de los servicios sanitarios prestados por centros dependientes del Sistema Sanitario P\u00fablico de Andaluc\u00eda. Bolet\u00edn Oficial de la Junta de Andaluc\u00eda (218), pp. 42-61.\u00a0https:\/\/juntadeandalucia.es\/boja\/2016\/218\/1; 2016. Accessed 20 Aug 2024."},{"key":"592_CR19","unstructured":"The CPI in one click, https:\/\/www.ine.es\/calcula\/index.do?L=1; 2021. Accessed 20 Aug 2024."},{"issue":"14","key":"592_CR20","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2147\/BCTT.S389696","volume":"9","author":"Y Lang","year":"2022","unstructured":"Lang Y, Wu B, Liu X. Economic evaluation of trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer in the United States. Breast Cancer (Dove Med Press). 2022;9(14):453\u201363. https:\/\/doi.org\/10.2147\/BCTT.S389696.","journal-title":"Breast Cancer (Dove Med Press)."},{"key":"592_CR21","unstructured":"Vallejo-Torres L, Garc\u00eda-Lorenzo B, Castilla I, Valc\u00e1rcel Nazco C, Garc\u00eda P\u00e9rez L, Linertov\u00e1 R, Serrano-Aguilar P. Valor Monetario de un A\u00f1o de Vida Ajustado por Calidad: Estimaci\u00f3n emp\u00edrica del coste de oportunidad en el Sistema Nacional de Salud. Ministerio de Sanidad, Servicios Sociales e Igualdad. Servicio de Evaluaci\u00f3n del Servicio Canario de la Salud; 2015. Informes de Evaluaci\u00f3n de Tecnolog\u00edas Sanitarias, https:\/\/www3.gobiernodecanarias.org\/sanidad\/scs\/content\/3382aaa2-cb58-11e5-a9c5-a398589805dc\/SESCS%202015_Umbral%20C.O.%20AVAC.pdf. Accessed 20 Aug 2024."},{"issue":"2","key":"592_CR22","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.gaceta.2019.06.007","volume":"34","author":"JA Sacrist\u00e1n","year":"2020","unstructured":"Sacrist\u00e1n JA, Oliva J, Campillo-Artero C, Puig-Junoy J, Pinto-Prades JL, Dilla T, et al. What is an efficient health intervention in Spain in 2020? Gac Sanit. 2020;34(2):189\u201393. https:\/\/doi.org\/10.1016\/j.gaceta.2019.06.007.","journal-title":"Gac Sanit"},{"key":"592_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.breast.2021.04.004","volume":"58","author":"A Olry de Labry Lima","year":"2021","unstructured":"Olry de Labry Lima A, \u0160pac\u00edrov\u00e1 Z, F\u00e9nix-Caballero S, Hoces AM, Vegas AS, Aranzana MC, et al. Cost-utility of talazoparib monotherapy treatment for locally advanced or metastatic breast cancer in Spain. Breast. 2021;58:27\u201333. https:\/\/doi.org\/10.1016\/j.breast.2021.04.004.","journal-title":"Breast"},{"key":"592_CR24","unstructured":"Breastcancer.org. Estado del c\u00e1ncer de mama con respecto a los receptores de hormonas, https:\/\/www.breastcancer.org\/es\/informe-patologico\/estado-receptores-hormonas?gclid=Cj0KCQjwuZGnBhD1ARIsACxbAVgTM15z5mp_awCyKOh5QF6ibNDIJyZ2Z-6LgbXzO0NVAL79Oo8SUnQaArKaEALw_wcB; 2023. Accessed 20 Aug 2024."},{"issue":"15","key":"592_CR25","doi-asserted-by":"publisher","first-page":"175883592311699","DOI":"10.1177\/17588359231169983","volume":"21","author":"J Yang","year":"2023","unstructured":"Yang J, Han J, Zeng N, Yan X. Cost-effectiveness of trastuzumab deruxtecan in previously treated human epidermal growth factor receptor 2-low metastatic breast cancer. Ther Adv Med Oncol. 2023;21(15):17588359231169984. https:\/\/doi.org\/10.1177\/17588359231169983.","journal-title":"Ther Adv Med Oncol."},{"issue":"8","key":"592_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0290507","volume":"18","author":"D Shi","year":"2023","unstructured":"Shi D, Liang X, Li Y, Chen L. Cost-effectiveness of trastuzumab deruxtecan for previously treated HER2-low advanced breast cancer. PLoS ONE. 2023;18(8): e0290507. https:\/\/doi.org\/10.1371\/journal.pone.0290507.","journal-title":"PLoS ONE"},{"issue":"4","key":"592_CR27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1177\/0272989X16670617","volume":"37","author":"C Williams","year":"2017","unstructured":"Williams C, Lewsey JD, Mackay DF, Briggs AH. Estimation of survival probabilities for use in cost-effectiveness analyses: a comparison of a multi-state modeling survival analysis approach with partitioned survival and markov decision-analytic modeling. Med Decis Making. 2017;37(4):427\u201339. https:\/\/doi.org\/10.1177\/0272989X16670617.","journal-title":"Med Decis Making"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-025-00592-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-025-00592-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-025-00592-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T13:31:18Z","timestamp":1756733478000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-025-00592-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["592"],"URL":"https:\/\/doi.org\/10.1007\/s41669-025-00592-0","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]},"assertion":[{"value":"15 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors state that they have no relevant conflict of interests which could have an impact on study design, analysis or the presentation of findings.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"The present research work was conducted without funding.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors made a meaningful contribution to the conception, design, analysis and interpretation of data, elaboration and critical review of the manuscript, approved the final manuscript and agreed to assume responsibility for all aspects of the work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"The corresponding author, on behalf of all other co-signatories, guarantees the accuracy, transparency and veracity of the data and information contained in the present manuscript. They also guarantee that no relevant information has been omitted and that all disagreements between authors have been appropriately resolved and discussed.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of Transparency"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable as no human participants were involved in this study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable, as no patient data or individual participant information is included in this study.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The data inputs used in the analyses\u2014including clinical efficacy, utility values, and cost parameters\u2014are described in detail in the manuscript and supplementary materials and were obtained from published literature and official Spanish healthcare databases. Any additional datasets generated during the current study are available from the corresponding author upon reasonable request.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"The economic evaluation and budget impact analysis were conducted using Microsoft Excel 2016, employing a partitioned survival model to estimate costs and health outcomes. The Excel model(s) used for these analyses are available from the corresponding author upon reasonable request.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}